New Biologic Entity (NBE) Research in Switzerland

Investing in groundbreaking technologies, platforms and facilities ensures that we will continue to drive innovation within our pipeline. In 2006, the Glenmark Biologics Research Centre opened in the canton of Neuchâtel, Switzerland. Our newest translational discovery center in Lausanne was opened in 2018. Both Swiss research centers focus on the discovery and development of NBEs, comprising GBR 830, an anti-OX40 monoclonal antibody being developed to treat atopic dermatitis, as well as other monoclonal antibodies based on Glenmark’s BEAT® [Bispecific Engagement by Antibodies based on the T-cell receptor] platform. Operations in Switzerland include end-to-end capabilities to discover and develop NBEs from inception through preclinical and clinical studies.

With a world-class, GMP-certified manufacturing line in our Neuchâtel location, the facility provides Glenmark with a full suite of in-house capabilities necessary for early production of investigational biologics, including conducting translational studies, cell line development, bioassay development and antibody engineering, as well as up- and downstream development. Our team conducts the scientific investigation to support the clinical development of our product candidates, translating basic research into potential new therapies that may one day benefit patients.

New Chemical Entity (NCE) Research in India 

Located in Mahape, on the outskirts of Mumbai, India, our R&D center has end-to-end capabilities for discovery and development of NCEs, from target selection to clinical development. The 125,000-square-foot research facility is equipped with the state-of-the-art infrastructure required to carry out research activities like medicinal chemistry, process and analytical chemistry, in vitro and in vivo studies, as well as project management.